Nomura has reiterated its buy rating on Lupin with a target price of ₹2,350 per share following the company’s latest regulatory milestone. The stock is currently trading at ₹1,952.00.
Lupin has received US FDA approval for gRisperdal Consta, becoming the second company globally and the first Indian generic manufacturer to secure clearance for the product. Nomura said this approval strengthens Lupin’s position in the complex generics space, which remains a key driver of long-term growth.
The brokerage added that gRisperdal Consta builds on the company’s prior US FDA approvals for gGlucagon and gVictoza, further reinforcing its strategy of targeting high-value, difficult-to-manufacture products.
Nomura believes Lupin’s expanding pipeline of complex generics enhances its competitiveness in the US market, while also supporting margin expansion over the medium term.
Disclaimer: This article is based on brokerage views as cited. The views expressed are those of the brokerage and do not represent investment advice.
